News

Based on the results, which demonstrated strong efficacy and good tolerability, the company says it will continue developing SPP635 in phase II in a special population of diabetic

Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer. The companies also confirmed that they are planning a company-sponsored phase III

The trial is designed to evaluate the therapeutic effect of its SCV-07 compound on patients with HCV. The objective of the trial is to demonstrate SCV-07’s effect on

Actos directly targets insulin resistance in type II diabetics, a condition where the body does not effectively use the insulin it produces, by improving the sensitivity to insulin

Tranzyme is developing TZP-101 as a first-in-class gastroprokinetic agent for the treatment of severe gastroparesis and post-operative ileus (POI). The data from its pilot phase IIa study was

The drug will treat patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery. The French drug maker, the third

Although response rates were similar in both arms, the trial did not meet its primary objective of demonstrating that CellCept was superior to intravenous cyclophosphamide (IVC) in inducing

Of the 332 patients enrolled, 148 patients have already completed the required six months of treatment. The company expects to have the last patient complete the six months

KP-1461 id a viral decay acceleration agent, inducing mutations within the HIV genome leading to degraded viral fitness and viral collapse. This is contrast to most HIV treatments